Prospective, comparative study of different dosages of ATG used in conditioning of HLA haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001761

Enrollment

Unknown

Registered

2011-12-01

Start date

2010-01-20

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hematological malignancies

Interventions

A:ATG6mg/kg

B:ATG 10mg/kg

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age: 15-60y; indicated for related haploidentical HSCT; standard risk hematological malignancies; signed consent form.

Exclusion criteria

Exclusion criteria: Allergic to ATG; unconsented.

Design outcomes

Primary

Measure	Time frame
acute GVHD;	—

Countries

China

Contacts

Public ContactHuang Xiaojun

xjhrm@medmail.com.cn+86 10 88326000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 22, 2026